Abstract
Methods A systematic screening program of oncogenic HPV infection has been initiated in 2002 in HIV+ women; oncogenic HPV was detected by Hybrid Capture II (Digene®) amplification test performed on cervical smears. Women were classified in three groups based on their screening test: N = negative for HPV; P = positive HPV and no cervical high-grade dysplasic lesion; PN = positive HPV then negative on follow-up (FU). The three groups were compared in terms of demographics, CD4, viral load (VL), HIV history and HAART.
Highlights
We have evaluated the prevalence of oncogenic human papillomavirus (HPV) cervical infection and its clearance in a cohort of HIV-infected women in the HAART era
A systematic screening program of oncogenic HPV infection has been initiated in 2002 in HIV+ women; oncogenic HPV was detected by Hybrid Capture II (Digene®) amplification test performed on cervical smears
80% of women in each group were treated with HAART and 67% had a viral load (VL)
Summary
Impact of HIV treatment on clearance of human papillomavirus (HPV) infection in HIV-infected women. Address: Saint Pierre University Hospital, Brussels, Belgium * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. Published: 10 November 2008 Journal of the International AIDS Society 2008, 11(Suppl 1):P289 doi:10.1186/1758-2652-11-S1-P289. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
